Is GeneDx Holdings Corp. overvalued or undervalued?
As of November 15, 2021, GeneDx Holdings Corp. is considered risky and overvalued due to negative financial ratios, including a Price to Book Value of 7.99 and an EV to EBITDA of 188.80, despite a strong recent stock performance.
As of 15 November 2021, the valuation grade for GeneDx Holdings Corp. moved from does not qualify to risky. The company is currently overvalued, as indicated by its significant negative financial ratios. The Price to Book Value stands at 7.99, while the EV to EBITDA is an alarming 188.80, and the ROE is at -11.17%. In comparison to its peers, GeneDx's P/E ratio is -63.58, while Aveanna Healthcare Holdings, Inc. has a P/E of 21.61, and Nutex Health, Inc. boasts a very attractive P/E of 4.26. These comparisons highlight the overvaluation of GeneDx relative to its industry peers. Despite a strong recent stock performance, with a 1-year return of 190.28% compared to the S&P 500's 10.26%, the underlying financial metrics suggest that the stock is not justified at its current price levels.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
